Venture(US:VEMLY) 智通财经网·2026-01-08 11:43Core Viewpoint - Guangdong Boma Medical Technology Co., Ltd. has applied for listing on the Shenzhen Stock Exchange's ChiNext board, with a fundraising target of 1.7 billion yuan, and is recognized as a leading provider of complex vascular disease intervention solutions globally [1][2]. Company Overview - Boma Medical specializes in the research, production, and global sales of high-performance vascular interventional medical devices, holding a leading position in the domestic market for vascular balloon catheters [1][2]. - The company has developed a comprehensive product matrix with over 50 product series, covering key areas such as coronary intervention, peripheral intervention, neuro intervention, blood dialysis pathways, and interventional accessories [1][2]. Research and Production - Boma Medical has established five R&D centers and laboratories globally, along with four production bases to ensure high-quality supply and scalability [1][2]. - The company has a strong focus on innovation, with significant R&D investments and a well-structured talent team, leading to multiple global breakthroughs in product technology and core processes [2]. Market Presence - The company's products are marketed in over 100 countries and regions, serving thousands of hospitals and medical centers worldwide, thereby establishing a strong brand image in the vascular interventional medical device market [2]. - Boma Medical has adopted a three-pronged business strategy of "innovation + scalability + internationalization," positioning itself as a significant player in the global vascular intervention industry [2]. Financial Performance - For the fiscal years 2022 to 2025, Boma Medical reported revenues of approximately 207 million yuan, 335 million yuan, 460 million yuan, and 303 million yuan respectively, with net profits of -36.06 million yuan, 25.99 million yuan, 76.78 million yuan, and 35.65 million yuan [3][4]. - As of June 30, 2025, the total assets of the company reached approximately 1.04 billion yuan, with a debt-to-asset ratio of 35.38% [4]. Market Share - According to Frost & Sullivan, Boma Medical holds a 9.6% market share in the Chinese coronary balloon dilation catheter market, ranking fourth overall and first among domestic brands [3]. - The company also holds a 4.7% market share in the Chinese peripheral artery balloon dilation catheter market, ranking fifth [3].